Trends in location of death for individuals with metastatic lung cancer in the United States.

Competing Interests: Declaration of competing interest Dr. Drilon reports the following disclosures: HONORARIA/ADVISORY BOARDS: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi, Liberum, Repare RX, Chugai, Merus, Chugai Pharmaceutical, Nuvalent, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology. ASSOCIATED RESEARCH PAID TO INSTITUTION: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar. ROYALTIES: Wolters Kluwer; OTHER: Merck, Puma, Merus, Boehringer Ingelheim. CME HONORARIA: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, AXIS, EPG Health, JNCC/Harborside. Dr. Gomez reports the following disclosures: HONORARIA: Varian Medical Systems, Merck, Bristol Myers Squibb, AstraZeneca, Reflexion Medical, Vindico Medical Education, US Oncology, GRAIL; CONSULTING OR ADVISORY ROLE: Olympus Medical Systems, Medtronic, Johnson & Johnson/Janssen. RESEARCH FUNDING: Merck, Varian Medical Systems, AstraZeneca, Bristol Myers Squibb. TRAVEL, ACCOMMODATIONS, EXPENSES: Varian Medical Systems, AstraZeneca, Merck, Vindico Medical Education, US Oncology, Driver, Inc. All other authors report no conflicts of interest.